Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Strategy for Extending Half-life in Drug Design and Its Significance.

Gunaydin H, Altman MD, Ellis JM, Fuller P, Johnson SA, Lahue B, Lapointe B.

ACS Med Chem Lett. 2018 Apr 2;9(6):528-533. doi: 10.1021/acsmedchemlett.8b00018. eCollection 2018 Jun 14.

2.

Extending 'predict first' to the design-make-test cycle in small-molecule drug discovery.

Harrison S, Lahue B, Peng Z, Donofrio A, Chang C, Glick M.

Future Med Chem. 2017 Apr;9(6):533-536. doi: 10.4155/fmc-2017-0025. Epub 2017 Apr 12. No abstract available.

PMID:
28402685
3.

Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.

Tian Y, Ma Y, Gibeau CR, Lahue BR, Shipps GW Jr, Strickland C, Bogen SL.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2735-8. doi: 10.1016/j.bmcl.2016.03.078. Epub 2016 Mar 23.

PMID:
27080185
4.

Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.

Bogen SL, Pan W, Gibeau CR, Lahue BR, Ma Y, Nair LG, Seigel E, Shipps GW Jr, Tian Y, Wang Y, Lin Y, Liu M, Liu S, Mirza A, Wang X, Lipari P, Seidel-Dugan C, Hicklin DJ, Bishop WR, Rindgen D, Nomeir A, Prosise W, Reichert P, Scapin G, Strickland C, Doll RJ.

ACS Med Chem Lett. 2016 Jan 20;7(3):324-9. doi: 10.1021/acsmedchemlett.5b00472. eCollection 2016 Mar 10.

5.

Health technology assessment on cervical cancer screening, 2000-2014.

Lahue BJ, Baginska E, Li SS, Parisi M.

Int J Technol Assess Health Care. 2015 Jan;31(3):171-80. doi: 10.1017/S0266462315000197. Review.

6.

Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus.

Chandran A, Bonafede MK, Nigam S, Saltiel-Berzin R, Hirsch LJ, Lahue BJ.

Am Health Drug Benefits. 2015 May;8(3):148-58.

7.

The budget impact of controlling wastage with smaller vials: A data driven model of session sizes in Bangladesh, India (Uttar Pradesh),Mozambique, and Uganda.

Yang W, Parisi M, Lahue BJ, Uddin M, Bishai D.

Vaccine. 2014 Nov 20;32(49):6643-8. doi: 10.1016/j.vaccine.2014.09.057.

8.

Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.

Ma Y, Lahue BR, Gibeau CR, Shipps GW Jr, Bogen SL, Wang Y, Guo Z, Guzi TJ.

ACS Med Chem Lett. 2014 Feb 24;5(5):572-5. doi: 10.1021/ml500019s. eCollection 2014 May 8.

9.

Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.

Pan W, Lahue BR, Ma Y, Nair LG, Shipps GW Jr, Wang Y, Doll R, Bogen SL.

Bioorg Med Chem Lett. 2014 Apr 15;24(8):1983-6. doi: 10.1016/j.bmcl.2014.02.055. Epub 2014 Feb 28.

PMID:
24656661
10.

Substituted piperidines as HDM2 inhibitors.

Ma Y, Lahue BR, Shipps GW Jr, Brookes J, Wang Y.

Bioorg Med Chem Lett. 2014 Feb 15;24(4):1026-30. doi: 10.1016/j.bmcl.2014.01.026. Epub 2014 Jan 17.

PMID:
24486134
11.

National burden of preventable adverse drug events associated with inpatient injectable medications: healthcare and medical professional liability costs.

Lahue BJ, Pyenson B, Iwasaki K, Blumen HE, Forray S, Rothschild JM.

Am Health Drug Benefits. 2012 Nov;5(7):1-10.

12.

Novel benzimidazole inhibitors bind to a unique site in the kinesin spindle protein motor domain.

Sheth PR, Shipps GW Jr, Seghezzi W, Smith CK, Chuang CC, Sanden D, Basso AD, Vilenchik L, Gray K, Annis DA, Nickbarg E, Ma Y, Lahue B, Herbst R, Le HV.

Biochemistry. 2010 Sep 28;49(38):8350-8. doi: 10.1021/bi1005283.

PMID:
20718440
13.

Substituted benzimidazoles: A novel chemotype for small molecule hKSP inhibitors.

Lahue BR, Ma Y, Shipps GW Jr, Seghezzi W, Herbst R.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3405-9. doi: 10.1016/j.bmcl.2009.05.040. Epub 2009 May 18.

PMID:
19481450
14.

The emerging infectious challenge of clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences.

O'Brien JA, Lahue BJ, Caro JJ, Davidson DM.

Infect Control Hosp Epidemiol. 2007 Nov;28(11):1219-27. Epub 2007 Oct 3.

PMID:
17926270
15.

Treatment of unruptured intracranial aneurysms: a nationwide assessment of effectiveness.

Higashida RT, Lahue BJ, Torbey MT, Hopkins LN, Leip E, Hanley DF.

AJNR Am J Neuroradiol. 2007 Jan;28(1):146-51.

16.

Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.

Bakhai A, Stone GW, Mahoney E, Lavelle TA, Shi C, Berezin RH, Lahue BJ, Clark MA, Lacey MJ, Russell ME, Ellis SG, Hermiller JB, Cox DA, Cohen DJ; TAXUS-IV Investigators.

J Am Coll Cardiol. 2006 Jul 18;48(2):253-61. Epub 2006 Jun 22.

18.

Supplemental Content

Support Center